Search hospitals > Ontario > TORONTO
Toronto General Hospital
Claim this profileTORONTO, Ontario M5G 2C4
Global Leader in Hepatitis
Global Leader in Lung Cancer
Conducts research for Hepatitis A
Conducts research for Kidney Disease
Conducts research for Heart Failure
396 reported clinical trials
25 medical researchers
Summary
Toronto General Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Hepatitis, Lung Cancer, Hepatitis A, Kidney Disease, Heart Failure and other specialties. Toronto General Hospital is involved with conducting 396 clinical trials across 412 conditions. There are 25 research doctors associated with this hospital, such as Eric Horlick, MD, Gary Lewis, MD, Erik Yeo, and David Cherney.Top PIs
Eric Horlick, MDToronto General Hospital6 years of reported clinical research
Studies Stroke
Studies Patent Foramen Ovale
6 reported clinical trials
12 drugs studied
Gary Lewis, MDUniversity of Arkansas for Medical Sciences2 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
6 reported clinical trials
14 drugs studied
Erik YeoToronto General Hospital6 years of reported clinical research
Studies Blood Clot
Studies Deep Vein Thrombosis
5 reported clinical trials
7 drugs studied
David CherneyToronto General Hospital1 year of reported clinical research
Studies Kidney Disease
Studies Diabetes
5 reported clinical trials
7 drugs studied
Clinical Trials running at Toronto General Hospital
Bipolar Disorder
Deep Vein Thrombosis
Blood Clot
Obesity
Paroxysmal Nocturnal Hemoglobinuria
Bleeding
Coronavirus
Embolism
Stroke
Atrial Septal Defect
Ketamine
for Treatment-Resistant Bipolar Depression
Growing evidence has supported rapid and robust antidepressant effects with subanesthetic doses of intravenous (IV) ketamine for treatment resistant depression (TRD). However, no completed or ongoing RCTs have evaluated the effects of repeated doses of IV ketamine for a homogenous sample of patients with treatment-resistant bipolar disorder depression (TRBD). The primary research goal is to determine the acute antidepressant efficacy, safety and tolerability of repeated sub-anesthetic maintenance doses of IV ketamine in, over a period of twelve weeks. Open-label ketamine infusions will be provided on a flexible schedule (every 2-4 weeks) with flexible dosing (0.5-1.0mg/kg over 40 minutes) titrated to optimize benefits, while minimizing the dosage and frequency over a 12-week extension period. All patients participating in this open-label study will have completed an acute course of infusions in a parent two-site, phase II, double-blinded midazolam-controlled RCT trial. In addition to this acute course of four infusions, a maximum of six infusions will be provided over the 12-week period. Secondary aims include evaluating effects of IV ketamine on suicidal ideations, quality of life, function and duration of effects. Herein, a two-site (University Health Network and Ontario Shores Centre for Mental Health Sciences), single-arm, open label, 12-week extension trial evaluating the effects of flexibly-dosed adjunctive ketamine infusions for TRBD to maintain antidepressant effects in participants who achieved an antidepressant response (MADRS decrease by \>50%) or remission (MADRS \< 12) following an acute course of four ketamine infusions is proposed. The primary outcome will be Montgomery-Åsberg Depression Rating Scale (MADRS) scores, determining by a linear mixed model from baseline to week 12. Secondary outcomes include evaluating response and remission rates, safety, tolerability (including treatment-emergent mania), and effects on suicidality, anxiety, quality of life, function and the duration of effects.
Recruiting3 awards Phase 2
Ketamine
for Bipolar Disorder
Growing evidence has supported rapid and robust antidepressant effects with subanesthetic doses of intravenous (IV) ketamine for treatment resistant depression (TRD). However, no completed or ongoing randomized control trials (RCTs) have evaluated the effects of repeated doses of IV ketamine for a homogenous sample of patients with treatment-resistant bipolar disorder (TRBD). The primary research goal is to determine the acute antidepressant efficacy, safety and tolerability of four repeated sub-anesthetic doses of IV ketamine in moderate to severe TRBD. Secondary aims include evaluating effects of IV ketamine on suicidal ideations, quality of life, function and duration of effects. Herein, a two-site (University Health Network and Ontario Shores Centre for Mental Health Sciences), phase II, double-blinded, midazolam-controlled, two-week RCT evaluating the efficacy, safety and tolerability of four flexibly-dosed adjunctive ketamine infusions (0.5-0.75mg/kg infused over 40 minutes) for acute treatment of moderate to severe TRBD (type I \& II) is proposed. The primary outcome will be Montgomery-Åsberg Depression Rating Scale (MADRS) scores, determining the between group difference in change from baseline to day 14, using analysis of covariance (ANCOVA), with 14-day MADRS as the outcome and baseline MADRS and stratification variables (sex, bipolar type) as covariates. Secondary outcomes include evaluating response and remission rates, safety, tolerability (including treatment-emergent mania), and effects on suicidality, anxiety, quality of life, function and the duration of effects (to day 28).
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Toronto General Hospital?
Toronto General Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Hepatitis, Lung Cancer, Hepatitis A, Kidney Disease, Heart Failure and other specialties. Toronto General Hospital is involved with conducting 396 clinical trials across 412 conditions. There are 25 research doctors associated with this hospital, such as Eric Horlick, MD, Gary Lewis, MD, Erik Yeo, and David Cherney.
Where is Toronto General Hospital located?
**Toronto General Hospital**
- **Address:** 200 Elizabeth St, Toronto, ON M5G 2C4.
- **Directions:** Head south on University Ave from College St. The hospital is located on your right.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Toronto General Hospital, the following contacts are available:
1. **Ontario Works - City of Toronto**:
- **Phone:** 1-888-999-1142
- **Website:** [Ontario Works Assistance](https://www.toronto.ca/community-people/employment-social-support/support-for-people-in-financial-need/assistance-through-ontario-works/)
- Offers financial aid for essentials like food, shelter, and health costs.
2. **Artists' Health Centre**:
- **Email:** financialaid.ahc@uhn.ca
- **Phone:** 416 603 5263
- **Address:** 440 Bathurst St, Toronto, ON M6T 2S6
- **Website:** [Artists' Health Centre Financial Assistance](https://www.artistshealthcentre.ca/displayPage.php?page=FinancialAssistance)
3. **University Health Network (UHN)**:
- **General Inquiries:**
- Princess Margaret Hospital: 416 946 2000
- Toronto General Hospital: 416 340 4800
- Toronto Western Hospital: 416 603 2581
- **Website:** [UHN Contact Us](https://www.uhn.ca/corporate/Pages/contact_us.aspx)
4. **Princess Margaret Cancer Centre Patient Information Line (Info Line)**:
- **Phone:** 416 946 4559
- **Hours:** Monday - Friday, 8:00 am to 4:30 pm
5. **Patient Relations**:
- **Phone:** 416 340 4907
- **Email:** patientrelations@uhn.ca
These resources offer support for healthcare and treatment-related costs.
What insurance does Toronto General Hospital accept?
Toronto General Hospital, part of the University Health Network (UHN), accepts various insurance plans. It is recommended to contact the hospital directly or check their official website for the most accurate and up-to-date information on insurance plans they accept. UHN offers compassionate care and advanced medical programs, grouping physicians, staff, services, and resources into 10 medical programs to provide specialized care and is a significant research and teaching hospital network in Canada.
For international students in Canada, the University Health Insurance Plan (UHIP) is mandatory, insured by Manulife and administered by Cowan Insurance Limited. Students must maintain their active registration status to remain eligible for UHIP coverage.
Expats moving to Toronto are covered by the publicly funded Ontario Health Insurance Plan (OHIP) if they are residents of Ontario province and spend more than six months of the year in the province. Expats without residence or work permits need private health insurance. Some expats choose private insurance for additional benefits not covered by OHIP, such as private hospital rooms and dental and optometry services.
What awards or recognition has Toronto General Hospital received?
Toronto General Hospital, a key component of the University Health Network (UHN) in Toronto, Ontario, is globally acclaimed for its outstanding patient care and pioneering research. It secured the third position in Newsweek's 2024 list of the world's best hospitals, trailing only behind Mayo Clinic and Cleveland Clinic. This accolade underscores UHN's dedication to enhancing healthcare through cutting-edge research, education, and patient services, along with its notable advancements in medical artificial intelligence.